| Autor: |
Lynning M; The Danish MS Society, Valby, Denmark., Hanehøj K; The Danish MS Society, Valby, Denmark., Westergaard K; The Danish MS Society, Valby, Denmark., Kjær Ersbøll A; National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark., Claesson MH; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark., Boesen F; Danish MS Hospitals, Haslev, Denmark., Skovgaard L; The Danish MS Society, Valby, Denmark. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of alternative and complementary medicine (New York, N.Y.) [J Altern Complement Med] 2021 Oct; Vol. 27 (10), pp. 832-840. Date of Electronic Publication: 2021 Jul 15. |
| DOI: |
10.1089/acm.2020.0510 |
| Abstrakt: |
Background: Cytokines have been found to play a role in the disease activity of multiple sclerosis (MS). Previous studies indicate that acupuncture can affect cytokine levels in persons with other inflammatory diseases. Objectives: The aim of this study is to investigate the effect of acupuncture on cytokine levels and health-related quality of life (HRQoL) in persons with MS. Materials and Methods: A single-blind, randomized controlled trial was performed. Participants ( n = 66) were randomized into three groups (real acupuncture, sham acupuncture, and reference). Participants in the real acupuncture and sham groups received six treatments during a period of 4 weeks. The serum levels of 11 pro- and anti-inflammatory cytokines (IFNγ, IL-1β, IL-6, IL-8, IL-12p70, IL-13, TNFα, IL-10, IL-4, IL-2, and IL-17A) were assessed at baseline, after 2 and 4 weeks of treatment, and 4 weeks after the final treatment. Changes in HRQoL were assessed using the Functional Assessment of Multiple Sclerosis questionnaire. Results: No statistically significant differences in plasma levels between the three groups were seen for either of the cytokines, nor were there any differences between the groups for HRQoL. Conclusions: In this study, the authors could not demonstrate that a 4-week acupuncture treatment had a measurable effect on the plasma levels of seven selected cytokines or on HRQoL among people with MS. The trial was registered with the ISRCTN registry as ISRCTN34352011. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
